Alnylam Pharmaceuticals (ALNY) vs Regeneron Pharmaceuticals (REGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Regeneron Pharmaceuticals (REGN) has outperformed Alnylam Pharmaceuticals (ALNY) over the past year, gaining 27.2% versus a loss of 51.2%. Over five years, REGN leads with a +34.1% price change compared with +7.6% for ALNY. Regeneron Pharmaceuticals is the larger company by market cap ($76.00 billion vs $30.05 billion), about 2.5 times the size, while Alnylam Pharmaceuticals is growing revenue faster (+65.2% vs +1.0%).
On valuation, Regeneron Pharmaceuticals trades at a lower forward P/E (12.0x vs 18.0x for Alnylam Pharmaceuticals). Regeneron Pharmaceuticals pays a dividend yielding 0.49%, while Alnylam Pharmaceuticals does not currently pay one. Regeneron Pharmaceuticals converts more of its revenue into profit, with a net margin of 31.4% versus 8.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALNY | REGN |
|---|---|---|
| Share price | $224.56 | $738.15 |
| Market cap | $30.05B | $76.00B |
| 1-day change | +0.07% | -0.54% |
| YTD return | -43.57% | -3.85% |
| 1-year return | -51.17% | +27.24% |
| 5-year return | +7.60% | +34.14% |
| P/E ratio (TTM) | 37.87 | 18.25 |
| Forward P/E | 18.01 | 12.01 |
| EPS (TTM) | $5.93 | $40.44 |
| Dividend yield | 0.00% | 0.49% |
| Annual dividend | $0.00 | $3.64 |
| Revenue (latest FY) | $3.71B | $14.34B |
| Revenue growth (YoY) | +65.19% | +0.99% |
| Net income (latest FY) | $313.75M | $4.50B |
| Gross margin | 81.77% | — |
| Operating margin | 13.51% | 24.95% |
| Net margin | 8.45% | 31.41% |
| 52-week high | $495.55 | $859.34 |
| 52-week low | $197.81 | $541.00 |
| Distance from 52-week high | -54.68% | -14.10% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +65.27% | +16.00% |
| Average volume | 1.84M | 739.67K |
| Shares outstanding | 133.81M | 101.14M |
| Employees | 2,500 | 15,410 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Regeneron Pharmaceuticals is about 2.5 times larger than Alnylam Pharmaceuticals by market value ($76.00B vs $30.05B).
- REGN has outperformed ALNY by 78.4 percentage points over the past year.
- Alnylam Pharmaceuticals trades at a higher earnings multiple (37.9x vs 18.3x trailing P/E).
- Regeneron Pharmaceuticals is more profitable, keeping 31.4 cents of every revenue dollar as net income versus 8.4 cents for Alnylam Pharmaceuticals.
- Alnylam Pharmaceuticals grew revenue faster in its latest fiscal year (+65.19% vs +0.99%).
About Alnylam Pharmaceuticals
ALNY stock →Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 2,500 employees
About Regeneron Pharmaceuticals
REGN stock →Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide.
Health Care · Biotechnology: Pharmaceutical Preparations · 15,410 employees
ALNY vs REGN FAQ
Which is bigger, Alnylam Pharmaceuticals or Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals (REGN) is larger, with a market capitalization of $76.00B compared with $30.05B for Alnylam Pharmaceuticals (ALNY).
Which stock has performed better over the past year, ALNY or REGN?
REGN returned +27.24% over the past 12 months, compared with -51.17% for ALNY (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ALNY or REGN?
REGN has the lower trailing P/E at 18.3, versus 37.9 for ALNY. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Alnylam Pharmaceuticals or Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals pays a dividend yielding 0.49%, while Alnylam Pharmaceuticals does not currently pay a regular dividend.
Are Alnylam Pharmaceuticals and Regeneron Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.